A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

被引:272
|
作者
Liu, Margaret A. [1 ]
机构
[1] ProTherImmune, 3656 Happy Valley Rd, Lafayette, CA 94549 USA
来源
VACCINES | 2019年 / 7卷 / 02期
关键词
DNA vaccine; mRNA vaccine; plasmid DNA; in vitro transcribed mRNA; immune responses; formulations; Cytolytic T Lymphocytes; antibodies; innate immunity; WEST-NILE-VIRUS; CYTOTOXIC T-LYMPHOCYTES; HEALTHY-ADULTS; INFLUENZA-VIRUS; INTRAMUSCULAR INJECTION; MITOCHONDRIAL TOXICITY; NEUTRALIZING ANTIBODY; RESPIRATORY-SYNDROME; IMMUNE-RESPONSES; OPEN-LABEL;
D O I
10.3390/vaccines7020037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.
引用
下载
收藏
页数:20
相关论文
共 50 条
  • [1] Plasmid vector design and technologies for DNA vaccine development
    Iurescia, S.
    Fioretti, D.
    Pierimarchi, P.
    Signori, E.
    Zonfrillo, M.
    Fazio, V. M.
    Rinaldi, M.
    HUMAN GENE THERAPY, 2013, 24 (12) : A168 - A169
  • [2] Developing mRNA-vaccine technologies
    Schlake, Thomas
    Thess, Andreas
    Fotin-Mleczek, Mariola
    Kallen, Karl-Josef
    RNA BIOLOGY, 2012, 9 (11) : 1319 - 1330
  • [3] Production of DNA vaccine against leishmaniasis: comparison of culture media and plasmid size
    Sanchez, Myriam
    Ortega, Jaime
    Dumonteil, Eric
    JOURNAL OF BIOTECHNOLOGY, 2010, 150 : S463 - S463
  • [4] Simulation for the recovery of plasmid for a DNA vaccine
    Limonta, Miladys
    Krajnc, Nika Lendero
    Vidic, Urska
    Zumalacarregui, Lourdes
    BIOCHEMICAL ENGINEERING JOURNAL, 2013, 80 : 14 - 18
  • [5] COMPARING vaccine manufacturing technologies recombinant DNA vs in vitro transcribed (IVT) mRNA
    Davidopoulou, Christina
    Kouvelas, Dimitrios
    Ouranidis, Andreas
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [6] Protection against tuberculosis by a plasmid DNA vaccine
    Lowrie, DB
    Silva, CL
    Colston, MJ
    Ragno, S
    Tascon, RE
    VACCINE, 1997, 15 (08) : 834 - 838
  • [7] Vaccine Developers Leverage mRNA and Other Powerful Technologies
    Grinstein J.
    Thomas U.
    Genetic Engineering and Biotechnology News, 2024, 44 (05): : 40 - 43
  • [8] Proven mRNA Technologies Embolden Vaccine and Drug Makers
    Raper V.
    Genetic Engineering and Biotechnology News, 2022, 42 (05): : 22 - 24
  • [9] Secure Splenic Delivery of Plasmid DNA and Its Application to DNA Vaccine
    Kurosaki, Tomoaki
    Kodama, Yukinobu
    Muro, Takahiro
    Higuchi, Norihide
    Nakamura, Tadahiro
    Kitahara, Takashi
    Miyakoda, Mana
    Yui, Katsuyuki
    Sasaki, Hitoshi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (11) : 1800 - 1806
  • [10] Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications
    Ferreira, GNM
    Monteiro, GA
    Prazeres, DMF
    Cabral, JMS
    TRENDS IN BIOTECHNOLOGY, 2000, 18 (09) : 380 - 388